- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Review, Journal: Superficial Venous Disease - An updated review. (Pubmed Central) - Jun 20, 2024 This review provides an update on the pathophysiology, classification, clinical features, and imaging findings as well as the conservative, pharmacological, and interventional treatment options indicated for different SVD pathologies. It aims to expedite the timely deployment of therapies geared toward reducing the significant morbidity associated with SVD especially varicose veins, venous ulcers, and venous insufficiency, to improve the quality of life of these patients and prevent complications.
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Varithena (Trianon Ballroom, 3rd Floor) - May 28, 2024 - Abstract #VEITH2024VEITH_912;
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Trial completion date, Trial primary completion date: Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (clinicaltrials.gov) - Feb 21, 2024 P4, N=100, Recruiting, It aims to expedite the timely deployment of therapies geared toward reducing the significant morbidity associated with SVD especially varicose veins, venous ulcers, and venous insufficiency, to improve the quality of life of these patients and prevent complications. Trial completion date: Nov 2026 --> Jun 2027 | Trial primary completion date: Feb 2024 --> Sep 2024
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
VeinGlobal Superficial Vein Theater (Americana 1 & 2) - Oct 18, 2023 - Abstract #IVC2024IVC_30; Perforator vein treatment (Maven device, Laser, Foam). Liquid and foam sclerotherapy of spider veins.
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Observational data, Journal: VIEW-VLU Observational Study of the Effect of Varithena on Wound Healing in the Treatment of Venous Leg Ulcers. (Pubmed Central) - Jun 19, 2023 Longer term studies are required to characterize the durability of MFA closure and sustained symptom relief in LD truncal veins. Treatment with 1% polidocanol microfoam was associated with promising wound healing rates and low recurrence rates for VLUs, despite a challenging patient population with recalcitrant ulcers, a large percentage of which were circumferential, in patients with high body mass indexes.
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Optimizing Treatment for Chronic Venous Insufficiency: The Power of Varithena (Waldorf Astoria Ballroom | Mezzanine Level) - May 13, 2023 - Abstract #NCVH2023NCVH_465; Treatment with 1% polidocanol microfoam was associated with promising wound healing rates and low recurrence rates for VLUs, despite a challenging patient population with recalcitrant ulcers, a large percentage of which were circumferential, in patients with high body mass indexes. Sponsored by Boston Scientific: NON-CME
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Varithena (Trianon Ballroom, 3rd Floor) - May 7, 2023 - Abstract #VEITH2023VEITH_1205;
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Enrollment open, Trial completion date: Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (clinicaltrials.gov) - Feb 17, 2023 P4, N=100, Recruiting, We also made recommendations on the concomitant vs staged treatment of varicose tributaries using phlebectomy, liquid or foam sclerotherapy (with physician compounded foam or commercially prepared polidocanol endovenous microfoam) in patients who undergo ablation of incompetent superficial truncal veins. Not yet recruiting --> Recruiting | Trial completion date: Aug 2026 --> Nov 2026
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Superficial Venous Disease: A primer for the Interventional Radiologist (Poster Hall ABC) - Jan 6, 2023 - Abstract #SIR2023SIR_705; Non-thermal ablations include ClariVein; VenaSeal and Varithena devices...Endovascular treatments have provided patients with additional options with shorter recovery times and lower complication rate. Trainees should be familiar with lower extremity vascular anatomy; indications for interventions; and post-intervention clinical management.
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
My Evolution with Varithena (Hyatt Regency, Empire C) - Aug 29, 2022 - Abstract #AVLS2022AVLS_45; This non-CME accredited activity is sponsored by Boston Scientific Sponsored By Boston Scientific
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Trial completion date, Trial initiation date, Trial primary completion date: Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (clinicaltrials.gov) - Jul 26, 2022 P4, N=100, Not yet recruiting, Closure rates in both groups were maintained 36 months after treatment. Trial completion date: Mar 2026 --> Jul 2026 | Initiation date: Jul 2022 --> Nov 2022 | Trial primary completion date: Jun 2023 --> Nov 2023
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Trial completion, Trial completion date: VIEW-VLU: Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU) (clinicaltrials.gov) - Sep 17, 2021 P=N/A, N=82, Completed, Endovenous microfoam ablation with Varithena ® is a safe and effective non-tumescent, non-thermal alternative to laser and radiofrequency ablation. Active, not recruiting --> Completed | Trial completion date: Feb 2021 --> Sep 2020
- |||||||||| Varithena (polidocanol endovenous microfoam) / Boston Scientific
Clinical, Journal: Results of Polidocanol Endovenous Microfoam in clinical practice. (Pubmed Central) - Apr 29, 2021 PEM is safe and effective for the treatment of saphenous reflux and varicosities. Early closure rates using PEM are maintained at 6 months and are comparable to results reported with non-thermal non-tumescent and thermal tumescent technologies.
- |||||||||| Varithena (polidocanol injectable foam) / Boston Scientific
Trial completion date: VIEW-VLU: Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU) (clinicaltrials.gov) - Nov 20, 2020 P=N/A, N=82, Active, not recruiting, Early closure rates using PEM are maintained at 6 months and are comparable to results reported with non-thermal non-tumescent and thermal tumescent technologies. Trial completion date: Aug 2021 --> Feb 2021
- |||||||||| Varithena (polidocanol endovenous microfoam) / Boston Scientific
Tips, Tricks And Limitations: Varithena (Floridian Ballroom (Salons G, H and I)) - Nov 19, 2020 - Abstract #VEITH2021VEITH_355;
|